FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address...
Apollomics™ partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion...
FOSTER CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (€œApollomics€ or the €œCompany€), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
Collaboration Utilizing PredicineCARE„ Blood cfDNA NGS Assay Marks Progress in Employing Comprehensive Genomic Profiling for Detection of Select Alteration
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (œApollomics or the œCompany), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Apollomics or the Company), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat...
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the œCompany), today announced a report by the Veneto Institute of Oncology on the efficacy response of a...
FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the œCompany), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash,...